Zalutumumab in Non-curable Patients With SCCHN

Summary

Treatment, In combination with BSC, Open-label, Single arm, Efficacy Study.

Timeline

Start

2008-01

Primary completion

2011-08

Completion

2011-08

Publications

• Saloura V, Cohen EE, Licitra L, Billan S, Dinis J, Lisby S, Gauler TC. An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol. 2014 Jun;73(6):1227-39. doi: 10.1007/s00280-014-2459-z. Epub 2014 Apr 9.

Drugs

Indications